In clinical trials in both adults and children with EoE, anti-IL-5 biologics have been able to reduce mucosal and peripheral eosinophilia but have often missed their primary aims with regards to degree of eosinophil reduction or symptom improvement. This evidence concerns the gene IL5 and eosinophilic esophagitis.